Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis

Table 1 Clinicopathological features of CML with 11q23 translocation

#	Sex/age ^a	Treatment ^b	Interval ^c	11q23 phase ^d	TKI ^e	Treatment response		F/U from CML ^f	F/U from 11q23 ^g	Status at last F/U
#	Sex/age ^a					CCyR	MMR
1	F/64	Imatinib	17	CP (1% blasts)	Yes	Yes	Yes	68	50.2	Alive
2	M/43	IFNa, Imatinib, Dasatinib	172	AP (12% blasts)	Yes	No	No	186	13.9	Dead
3	M/67	IFNa, Hydroxyurea	17	AP (12% blasts)	Yes	No	N/A	33	16.6	Dead
4	F/50	IFNa	7	BP	Yes	No	No	8	0.9	Dead
5	M/70	None	0	BP	Yes	Yes	Yes	7	6.9	Alive
6	M/31	None	0	BP	Yes	NK	NK	8	8	Dead
7	F/21	Hydroxyurea, Imatinib	12	BP	Yes	No	No	21	9.5	Dead
8	M/47	Hydroxyurea, Imatinib	13	BP	Yes	No	No	16	2.4	Dead
9	M/59	Hydroxyurea, IFNa, Imatinib	13	BP	No			14	0.8	Dead
10	F/50	Hydroxyurea, IFNa	12	BP	No			17	5.3	Dead
11	M/48	Nilotinib, Imatinib, Dasatinib	32	BP	No			36	4.1	Dead

CCyR complete cytogenetic response, MMR major molecular response, N/A not available, NK not known as the patient had concurrent chemotherapy with daunorubincin and ara-C.
^aAge at initial diagnosis of CML.
^bInitial treatments before 11q23 emergence.
^cInterval (month) between CML diagnosis and 11q23 appearance.
^dCML phase in which 11q23 developed.
^eTKI treatment after 11q23 clonal evolution.
^fTime (month) from CML diagnosis to the last follow-up.
^gTime (month) from 11q23 emergence to the last follow-up.

ISSN: 1756-8722